Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2024 Jan 23;14:1369562. doi: 10.3389/fonc.2024.1369562

Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions

Daniele Generali 1,2,*, Rossana Berardi 3, Michele Caruso 4, Marina Cazzaniga 5,6, Ornella Garrone 7, Ida Minchella 8, Ida Paris 9, Carmine Pinto 10, Sabino De Placido 11
PMCID: PMC10848318  PMID: 38327748

In the published article, there was an error in affiliation 8. Instead of “Division of Early Drug Development, European Institute of Oncology, Milan, Italy”, it should be “Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES